4 citations
,
November 2024 in “Cell Biology and Toxicology” Blocking certain receptors in the lungs might help treat a specific type of asthma.
3 citations
,
September 2021 in “Journal of Investigative Dermatology” Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
1 citations
,
October 2025 in “Journal of Allergy and Clinical Immunology” A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
3 citations
,
June 1993 in “Hair transplant forum international” The document's conclusion cannot be provided because the content is not available to parse.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
2 citations
,
September 1998 in “Der Hautarzt” A gene mutation causes a rare hereditary hair loss, offering potential for new treatments.
6 citations
,
December 2018 in “Ophthalmic Plastic and Reconstructive Surgery” Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.
January 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Botulinum toxin type A did not help regrow hair in severe alopecia cases.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
November 2025 in “Mendeley Data” November 2025 in “Mendeley Data” The treatment was not recommended due to limited effectiveness and significant side effects.
October 2019 in “The Permanente Journal” The author improved his health by adopting mindfulness and a healthier lifestyle.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
January 2017 in “Springer eBooks”
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Derinat helps extend hair growth by reducing harmful molecules in skin cells.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
October 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.
January 2017 in “Hair transplant forum international” The document's content could not be processed.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” 3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
2 citations
,
January 2015
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
July 2022 in “British Journal of Dermatology” February 2019 in “Dermatologic Surgery” January 2019 in “Dermatologic Surgery” July 2018 in “Dermatologic Surgery”